Interestingly, a recent exploratory study suggested that the KRASG12C-mutation could be associated with a prolonged response to 1 L immunotherapy in PD-L1-overexpressing NSCLC [32]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.